Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy
Fouad T. Chebib, Vicente E. Torres
American Journal of Kidney Diseases (2021) Vol. 78, Iss. 2, pp. 282-292
Closed Access | Times Cited: 67

Showing 1-25 of 67 citing articles:

KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Olivier Devuyst, Curie Ahn, Thijs R.M. Barten, et al.
Kidney International (2025) Vol. 107, Iss. 2, pp. S1-S239
Open Access | Times Cited: 4
Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease
Djalila Mekahli, Lisa M. Guay‐Woodford, Melissa A. Cadnapaphornchai, et al.
Clinical Journal of the American Society of Nephrology (2023) Vol. 18, Iss. 1, pp. 36-46
Open Access | Times Cited: 24
GANAB-Associated Severe Autosomal Dominant Polycystic Kidney Disease in an 18-Year-Old Female: A Case Report
Gautam Agrawal, Bhawna Agarwal, Anjana Chandrasekhara Pillai, et al.
Cureus (2025)
Open Access | Times Cited: 1
Biomarkers of Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease
Ahmad Ghanem, Abdul Hamid Borghol, Fadi George Munairdjy Debeh, et al.
Kidney International Reports (2024) Vol. 9, Iss. 10, pp. 2860-2882
Open Access | Times Cited: 7
Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease
Thomas Bais, Ron T. Gansevoort, Esther Meijer
Drugs (2022) Vol. 82, Iss. 10, pp. 1095-1115
Open Access | Times Cited: 24
Emerging Role of Clinical Genetics in CKD
Prasad Devarajan, Glenn M. Chertow, Katalin Suszták, et al.
Kidney Medicine (2022) Vol. 4, Iss. 4, pp. 100435-100435
Open Access | Times Cited: 19
Risk Severity Model for Pediatric Autosomal Dominant Polycystic Kidney Disease Using 3D Ultrasound Volumetry
Luc Breysem, Frederik De Keyzer, Pieter Schellekens, et al.
Clinical Journal of the American Society of Nephrology (2023) Vol. 18, Iss. 5, pp. 581-591
Open Access | Times Cited: 12
Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD
Francisco Roca Oporto, Cristina Andrades Gómez, Gema Montilla Cosano, et al.
Kidney International Reports (2024) Vol. 9, Iss. 4, pp. 1031-1039
Open Access | Times Cited: 4
Cilia-enriched oxysterol 7β,27-DHC is required for polycystin ion channel activation
Kodaji Ha, Nadine Mundt, Paola Bisignano, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update
Matthew Gittus, Helen Haley, Tess Harris, et al.
BMC Nephrology (2025) Vol. 26, Iss. 1
Open Access
Therapeutic opportunities in polycystic kidney and liver disease through extracellular matrix dynamics
Adrián Cordido, Laura Núñez-González, Olaya Lamas-González, et al.
Biochemical Pharmacology (2025), pp. 116858-116858
Closed Access
Impact of Chronic Kidney Disease on Aortic Dissection in Patients with Polycystic Kidney Disease: A Fifteen-year Nationwide Population-based Cohort Study in Taiwan
Chia-Ning Fan, Chi-Hsiang Chung, Wu-Chien Chien, et al.
International Journal of Medical Sciences (2025) Vol. 22, Iss. 7, pp. 1493-1503
Open Access
Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options
Yeshwanter Radhakrishnan, Parikshit Duriseti, Fouad T. Chebib
Kidney Research and Clinical Practice (2022) Vol. 41, Iss. 4, pp. 422-431
Open Access | Times Cited: 16
Long-Term Effects of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Predictors of Treatment Response and Safety over 6 Years of Continuous Therapy
Mai Yamazaki, Haruna Kawano, Miho Miyoshi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2088-2088
Open Access | Times Cited: 3
Autosomal Dominant Polycystic Kidney Disease
Maria Lourdes Gonzalez Suarez, Silvia Titan, Neera K. Dahl
Advances in Kidney Disease and Health (2024) Vol. 31, Iss. 6, pp. 496-503
Closed Access | Times Cited: 3
Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies
Fouad T. Chebib, Xiaolei Zhou, Diana Garbinsky, et al.
Kidney Medicine (2023) Vol. 5, Iss. 6, pp. 100639-100639
Open Access | Times Cited: 7
HYDROchlorothiazide versus placebo to PROTECT polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trial
Thomas Bais, Esther Meijer, Bart J. Kramers, et al.
Trials (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Polycystic Kidney/Liver Disease
Rebecca Roediger, Douglas T. Dieterich, Pramodh Chanumolu, et al.
Clinics in Liver Disease (2022) Vol. 26, Iss. 2, pp. 229-243
Closed Access | Times Cited: 12
Echocardiographic Abnormalities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients
Mariana Pfeferman, Daniel Ribeiro da Rocha, Fernanda Guedes Rodrigues, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 20, pp. 5982-5982
Open Access | Times Cited: 12
Perspectives on Drug Development in Early ADPKD
Djalila Mekahli, Hayley Womack, Neera K. Dahl
Clinical Journal of the American Society of Nephrology (2022) Vol. 17, Iss. 10, pp. 1555-1558
Open Access | Times Cited: 11
An Artificial Intelligence Generated Automated Algorithm to Measure Total Kidney Volume in ADPKD
Jonathan Taylor, Richard Thomas, Peter Metherall, et al.
Kidney International Reports (2023)
Open Access | Times Cited: 6
Metabolism-based approaches for autosomal dominant polycystic kidney disease
Ivona Bakaj, Alessandro Pocai
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 5
Probenecid slows disease progression in a murine model of autosomal dominant polycystic kidney disease
Sergey N. Arkhipov, D’Anna L. Potter, Regina F. Sultanova, et al.
Physiological Reports (2023) Vol. 11, Iss. 7
Open Access | Times Cited: 5
Magnetic Resonance Imaging in Clinical Trials of Diabetic Kidney Disease
Iris Friedli, Seema Baid‐Agrawal, Robert J. Unwin, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 14, pp. 4625-4625
Open Access | Times Cited: 5
Mayo imaging classification is a good predictor of rapid progress among Korean patients with autosomal dominant polycystic kidney disease: results from the KNOW-CKD study
Hayne Cho Park, Yeji Hong, Jeong-Heum Yeon, et al.
Kidney Research and Clinical Practice (2022) Vol. 41, Iss. 4, pp. 432-441
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top